Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial

BACKGROUND: There is an urgent need to develop additional treatment strategies for patients with treatment-resistant depression (TRD). The rapid but short-lived antidepressant effects of intravenous (IV) ketamine as a racemic mixture have been shown repeatedly in this population, but there is still...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith-Apeldoorn, Sanne Y., Veraart, Jolien K. E., Kamphuis, Jeanine, van Asselt, Antoinette D. I., Touw, Daan J., aan het Rot, Marije, Schoevers, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884875/
https://www.ncbi.nlm.nih.gov/pubmed/31783823
http://dx.doi.org/10.1186/s12888-019-2359-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884875/
https://www.ncbi.nlm.nih.gov/pubmed/31783823
http://dx.doi.org/10.1186/s12888-019-2359-1

Ejemplares similares